Influenza hemagglutinin displayed on self-assembling Q11 peptide nanofibers with a peptide adjuvant (KEYA) generated broadly protective antibodies recognizing flu variants spanning up to 30 years of antigenic drift and protected mice from lethal challenge.
30 years of antigenic drift coveredThe optimized SrtA-conjugated peptide nanofiber vaccine generated antibodies that significantly bound HA trimers from flu variants spanning up to 30 years of evolution from the immunizing antigen.
What the researchers found
Two methods of conjugating hemagglutinin (HA) to Q11 peptide nanofibers were demonstrated:
1. β-tail co-assembly: Produced increased antibody responses; with KEYA adjuvant, achieved modest increases in antibody breadth and survival against flu challenge
2. SortaseA (SrtA)-mediated ligation: Superior results — augmented antibody responses, significantly increased breadth of antibody binding to HA trimers spanning up to 30 years of antigenic drift from the immunizing antigen, increased hemagglutination inhibition to both homologous and heterologous viruses, and protected against lethal influenza challenge
The KEYA peptide adjuvant (random combinations of lysine, glutamic acid, tyrosine, and alanine) provided non-reactogenic immune enhancement without disrupting HA antigenicity at low concentrations.
Why it matters
Influenza kills hundreds of thousands of people annually, and the need for yearly vaccine reformulation is a major public health challenge. A vaccine platform that generates broadly protective antibodies against decades of viral evolution could dramatically reduce the burden of seasonal flu and improve pandemic preparedness. Self-assembling peptide nanofibers offer a modular, scalable platform that is non-reactogenic (fewer side effects) and can be adapted to display different antigens — potentially for other pathogens as well.
How the study worked
Researchers conjugated influenza hemagglutinin to Q11 self-assembling peptide nanofibers using two methods: β-tail co-assembly and SortaseA-mediated enzymatic ligation. The KEYA polypeptide adjuvant was incorporated into nanofiber formulations at varying concentrations. HA antigenicity was verified after conjugation. Mice were immunized and immune responses assessed by ELISA (antibody binding breadth to HA trimers from different flu variants spanning decades), hemagglutination inhibition assays (functional antibody activity), and lethal influenza challenge experiments (survival).
What this study cannot tell us
All experiments were conducted in mice, whose immune responses differ from humans. The 30-year antibody breadth was measured by binding assays, which may not perfectly predict protection against live virus in humans. Durability of the immune response beyond the study period is unknown. Manufacturing scalability and cost of SortaseA-mediated conjugation at commercial scale need evaluation. The study used a single HA subtype; performance against other influenza subtypes (e.g., H3N2, influenza B) was not tested.
How to read the evidence
This is a preclinical vaccine development study in mice with comprehensive immunological assessment including binding assays, functional antibody tests, and lethal challenge experiments. The progression through multiple conjugation strategies and the breadth of immunological analyses are strengths, though all findings remain in animal models.
When this study was published
Published in 2026, this is a very current study at the cutting edge of peptide nanofiber vaccine technology. The pursuit of broadly protective influenza vaccines is an active and competitive research area.
The bigger picture
Self-assembling peptide nanofibers represent a growing class of biomaterials for vaccine development. Unlike traditional adjuvants (like aluminum salts) that can cause side effects, peptide-based adjuvants like KEYA offer immune stimulation without reactogenicity. The Q11 platform has been explored for vaccines against various pathogens. This study's demonstration of broadly cross-reactive flu antibodies positions peptide nanofibers as a potential foundation for universal influenza vaccines — one of the most sought-after goals in vaccinology.
Questions still open
- Could this peptide nanofiber platform be used to create a truly universal flu vaccine covering both influenza A and B?
- How long do the broadly cross-reactive antibodies persist after immunization with nanofiber vaccines?
- Can the Q11-KEYA platform be adapted for other pathogens like SARS-CoV-2, RSV, or HIV using similar antigen display strategies?
Common questions
What is a self-assembling peptide nanofiber vaccine?
Could this lead to a flu shot that doesn't need yearly updating?
Read the original research
Presentation of hemagglutinin on adjuvant-bearing self-assembling peptide nanofibers increases heterologous responses against influenza.
Acta biomaterialia, 209, 211-224
Citation
Roe, Emily F; Votaw, Nicole L; Lazar, Kat M; Burke, Kaitlyn N; Miranda, Hector A; Fries, Chelsea N; Rock, Michelle L; Macintyre, Andrew N; Stover, Erica L; Huskey, Jessica B; Harris, Summer J; Landon, Chelsea D; Mansouri, Katayoun; Edwards, Robert J; Heaton, Nicholas S; Collier, Joel H. (2026). Presentation of hemagglutinin on adjuvant-bearing self-assembling peptide nanofibers increases heterologous responses against influenza.. Acta biomaterialia, 209, 211-224. https://doi.org/10.1016/j.actbio.2025.11.025